ClinicalTrials.gg
CompletedNCT03293732Updated Jan 7, 2020

Study of the Safety, Tolerability and Immunogenicity of an Intranasal Influenza Vaccine Administered to Healthy Adults

A Phase 1 interventional study of DCB07010 and HA antigens in Flu, Human, sponsored by Advagene Biopharma Co. Ltd.. Completed at 1 site in Taiwan. Open to participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-07.

Sponsored by Advagene Biopharma Co. Ltd. · Phase 1, Interventional, and Prevention

From the registry’s dates

  • Registered 4 years 9 months after the study started (first participant enrolled Nov 2012, registered Sep 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 52 studies in Influenza, Human with a site in Taiwan — 6 open to participants now, 6 under way, 2 of them phase 3. Influenza, Human · Taiwan.

Enrollment
47th of 47
36 · median 300
Started
2012
with 5 others
Phase 1
2 of 52
none open now
Registered
33rd of 52
by date
Lead sponsor
2 of 52
Advagene Biopharma Co. Ltd.

Among the 52 studies in Influenza, Human with a site in Taiwan, this one is the 47th largest by enrollment of the 47 interventional ones that give a count, is one of 6 that started in 2012, is one of 2 in phase 1, and was the 33rd registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

6 of the 52 studies in Influenza, Human with a site in Taiwan are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 20 Years to 40 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Influenza, Human with a site in Taiwan, or all of them as a file.
02

Study summary

The objectives of this study were to assess the safety and tolerability of DCB07010 when given intranasally at escalating dose levels of 7.5μg, 15μg, 30μg and 45μg, in combination with 22.5μg of influenza HA antigen (7.5μg HA of each of three strains) and to generate sufficient immunogenicity data to enable dose selection for larger and more definitive Phase 2 studies.

This was a single center, double-blind, randomized (2:1), dose-escalation study to assess the safety, tolerability and immunogenicity of 4 different vaccine-adjuvant doses in comparison to influenza HA alone. The 4 treatment cohorts were given DCB07010 in a dose- escalating manner.

03

Conditions studied

  • Flu, Human

Browse trials for

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Non-smoking adult aged between 20-40 years old;
  2. Physically and mentally healthy subjects as confirmed by an interview, medical history, clinical examination, chest X-rays, ophthalmoscopy, cardiac echo, and ;
  3. (BMI) between 18.5 and 25, inclusive, (BMI will be calculated as weight in kilogram [kg]/height in meters2 [m2]);
  4. Normal hematology, biochemistry and urinalysis determinations;
  5. Subject is willing and able to comply with study procedures and sign

Exclusion criteria

Exclusion Criteria:

  1. Subject with serious underlying chronic illness;
  2. Documented evidence of allergic rhinitis;
  3. Subject with acute sinusitis or chronic sinusitis accompanying acute symptoms within 3 days prior to enrollment;
  4. subjects as result of illness or treatment;
  5. Female subject of who:

    • is lactating; or
    • has positive urine pregnancy test at Visit 2 or Visit 3; or
    • refuse to adopt reliable method of during the study;
  6. Subject received blood products or immunoglobulin within 3 months prior enrollment;
  7. Subjects with long-term use of , including parenteral steroids or high dose inhaled steroids within 28 days prior to enrollment;
  8. Subject has received any intranasal medication or nasal topical treatment within 7 days prior to enrollment;
  9. Subject has received any agent within 28 days or 5 half- lives, whichever is longer, prior to the first dose of investigational product;
  10. Subject has previously experienced anaphylaxis;
  11. Subject has allergy to eggs or prior influenza vaccine;
  12. Subject with laboratory-confirmed influenza or has been vaccinated against influenza within 6 months prior to enrollment;
  13. Subject with acute respiratory illness or administered antibiotics or antivirals within 7 days prior to enrollment;
  14. Subject with body temperature high than 38°C within 3 days prior to enrollment;
  15. Subject with documented history of Bell's palsy or neurological disorder.
  16. Subject with documented history of diarrhea within one month prior to study enrollment
  17. A positive test for antibody.
  18. Subject has received Chinese medication or herbal medication within 28 days prior to enrollment
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Active comparator
    HA antigen only

    All subjects in this group received 2 doses of 22.2 μg HA antigens

    Biological: HA antigens

  • Experimental
    7.5 μg of DCB07010

    All subjects in this group received 7.5 μg of DCB07010 in 22.2 μg HA antigens twice.

    Biological: DCB07010 · Biological: HA antigens

  • Experimental
    15 μg of DCB07010

    All subjects in this group received 15 μg of DCB07010 in 22.2 μg HA antigens twice.

    Biological: DCB07010 · Biological: HA antigens

  • Experimental
    30 μg of DCB07010

    All subjects in this group received 30 μg of DCB07010 in 22.2 μg HA antigens twice.

    Biological: DCB07010 · Biological: HA antigens

  • Experimental
    45 μg of DCB07010

    All subjects in this group received 45 μg of DCB07010 in 22.2 μg HA antigens twice.

    Biological: DCB07010 · Biological: HA antigens

Interventions

  • BiologicalDCB07010

    A protein based adjuvant originated from prokaryotic organism.

  • BiologicalHA antigens

    HA antigens from three strains of influenza virus ( 7.5 μg of HA each strain).

06

What researchers measure

Primary outcomes

  1. Geometric Mean Titers (GMT) against all three strains of viral antigen

    Geometric Mean Titers (GMT) against all three strains of viral antigen after 2 doses of DCB07010 adjuvanted egg-derived vaccines or egg-derived vaccine. The geometric mean titers against all three-vaccine strains were assessed by egg-derived antigen haemagglutination inhibition (HI) assay. Statistic tests were two-sided and were set for alpha = 0.05. The purpose of this study was exploratory in safety and the formal statistical analysis was not necessary.

    Time frame: Day=0, 28

Secondary outcomes

  1. Geometric Mean Ratio (GMR) after 2 dose of vaccines

    Geometric Mean Ratio (GMR) after 2 dose of egg-based vaccine and DCB07010-adjuvanted vaccines. Statistic tests were two-sided and were set for alpha = 0.05. The purpose of this study was exploratory in safety and the formal statistical analysis was not necessary.

    Time frame: Day=0, 28

  2. Seroconversion Rates (SCR) measurements

    Seroconversion Rates (SCR) is defined the percentage of subjects with pre-vaccination HI titers \< 1:10 and a post-vaccination titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and at least a 4-fold increase in post-vaccination titer to each of the three vaccine components on Day 28.

    Time frame: Day=0, 28

07

Study locations

1 site
  • National Taiwan Univserity Hospital
    Taipei, 10002, Taiwan
08

References and documents

Publications

  • Pan SC, Hsieh SM, Lin CF, Hsu YS, Chang M, Chang SC. A randomized, double-blind, controlled clinical trial to evaluate the safety and immunogenicity of an intranasally administered trivalent inactivated influenza vaccine with adjuvant LTh(alphaK): A phase I study. Vaccine. 2019 Mar 28;37(14):1994-2003. doi: 10.1016/j.vaccine.2019.02.006. Epub 2019 Mar 2. PubMed 30837170 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2012 to primary completion in Mar 2013, 4 months.

Of 94 industry-sponsored phase 1 interventional studies under Influenza, Human, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 4 months is below that.

Counting every sponsor, half of 148 studies reached it within 11 months; a quarter within 4 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2017
First posted
Sep 26, 2017
StartActual
Nov 28, 2012
Primary completionActual
Mar 30, 2013
CompletionActual
Sep 30, 2013
Last update
Jan 7, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03293732
Lead sponsor
Advagene Biopharma Co. Ltd.
Responsible party
Sponsor
First posted
Sep 26, 2017
Start date
Nov 28, 2012
Primary completion
Mar 30, 2013
Completion
Sep 30, 2013
Last update
Jan 7, 2020

Study contacts

Shaun-Chwen Chang, Ph.D.
study chair · National Taiwan University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion